SPC504
Mirvetúxímabsoravtansín / Mirvetuximab soravtansine
Status:
UmsóknApplication date:
4.3.2025Application published:
15.4.2025
Max expiry date:
23.2.2036Medicine name:
ELAHEREMedicine for children:
No
Timeline
Today
4.3.2025Application
15.4.2025Publication
23.2.2036Expires
Marketing license
Foreign authorization number:
EU/1/24/1866Date:
14.11.2024
Owner
Name:
ImmunoGen, Inc.Address:
1 North Waukegan Road, North Chicago, IL 60064 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2538976